Management Of Iron Deficiency Anemia Research Articles

Effect of Nutritional Program on Anemic Status and Pregnancy outcome among Pregnant Women Suffering from Iron Deficiency Anemia

Background: Iron deficiency anemia (IDA) is the most common nutritional disorder during pregnancy. The aim of this study: was to determine the effect of nutritional program on anemic status and pregnancy outcome among pregnant women suffering from iron deficiency anemia. Subjects and Method: The study was carried out at antenatal inpatient units and outpatient clinics in obstetrics and gynecological department at Tanta University and El-Menshawy Hospitals and four governmental antenatal clinics in Tanta city. Convenient sample of 60 pregnant women were included in the study and fulfilling the inclusive criteria. Five tools were used: Tool (I):A structured interview schedule included four parts: (a) Socio-demographic data, (b) Reproductive history, menstrual history, antenatal booking and attendance of antenatal care classes regarding IDA, (c) Current health history of women included: medical, surgical and also family history (d) History of iron deficiency anemia during current pregnancy. Tool (II): Women's knowledge assessment interview: it included two parts: a) Women's knowledge about iron deficiency anemia and b): Assessment of pregnant women's self-care measures and nutritional habits regarding iron deficiency anemia. Tool (III): Iron Intake Calculation Food Frequency Questionnaire it was used to assess women's iron dietary intake. Tool (IV): Bio-physiological measurement included: (a) Anthropometric measurements :Body Mass Index and Mid Upper Arm Circumference (MUAC), (b) Physical examination: to assess signs of iron deficiency anemia, (c) Measurement of serum hemoglobin level on capillary blood using one touch hemoglobin device(d) Stool analysis: was done to exclude parasitic infestation. Tool (V): Outcome assessment tool: included two parts, (a) Maternal outcome assessment sheet and (b) Neonatal outcome assessment sheet. Results: Itrevealed that mean blood hemoglobin level had increased from (9.05±0.98) pre-program to (11.8±0.95) at the end of the 2nd trimester and (10.74±0.93) at the end of the 3rd trimester. Conclusion: Significant improvement of the level of knowledge, dietary habits, anemic status (hemoglobin level) and the maternal & neonatal outcome were found after implementation of the program. Therefore, the study recommended: developing antenatal educational classes for all pregnant women to increase their awareness about importance of early and regular antenatal care as well as proper screening for early diagnosis and effective management of IDA to improve their pregnancy outcome.

Diagnosis and Management of Iron Deficiency Anemia in Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is associated with extraintestinal manifestations in more than one-quarter of patients. Anemia is one of the most common concerns. Patients with IBD and comorbid iron deficiency anemia (IDA) are at risk for hospitalization and surgery, and IDA impacts health-related quality of life. IDA in IBD is often underdiagnosed and undertreated. Prompt treatment has the potential to improve patient quality of life and clinical outcomes. Although the treatment goals for IDA in IBD are well-defined, selecting a treatment is not as straightforward. Traditional oral iron replacement therapies are generally only recommended in patients with mild anemia who do not have active inflammatory disease. Novel oral iron formulations may circumvent some of the limitations associated with traditional oral products.

Perbandingan Efektivitas Ferric Carboxymaltose Dengan Ferrous Sulfate Sebagai Terapi Pasien Anemia Defisiensi Besi Pada Wanita Hamil

Background: Iron deficiency anemia is still a global problem, especially in pregnant women and causes maternal death due to bleeding. This is because the need for iron increases and the food supply decreases due to improper diet and nutritional patterns before pregnancy and during pregnancy. Iron supplements are an alternative in overcoming this problem, supplements are divided into two options, namely oral and parenteral. Objective: To compare the effectiveness of Ferric carboxymaltose with Ferrous sulfate as a treatment for iron deficiency anemia in pregnant women in terms of increased hemoglobin and ferritin levels. Method: Systematic Review, this research was sourced from online databases, namely: PubMed, Science direct, Garuda ristekbrin, Google scholar and Research gate with the keywords: ("iron deficiency anemia in pregnancy" OR "Anemia Pregnancy" OR "iron-deficient gravidas" ) AND ("Ferric carboxymaltose" OR "FCM" OR "iron dextri-maltose") AND ("Ferrous sulfate" OR "Ferrous Sulphate" OR "ammonium ferrous sulfate"). The data in this study were analyzed in a narrative manner with data extraction containing: name of journal, author, year, research design, sample and results with a search time limit of 2015-2020. Summary of results: this study found that Ferric carboxymaltose gave more improvement than Ferrous sulfate in terms of increasing hemoglobin and ferritin levels. Conclusion: The final result of this systematic review study is that Ferric carboxymaltose is more effective than Ferrous sulfate for the management of iron deficiency anemia in pregnant women in terms of increasing hemoglobin and ferritin levels.

Iron Deficiency Anemia in Celiac Disease.

The iron absorption process developsmainly in the proximal duodenum. This portion of the intestine is typically destroyed in celiac disease (CD), resulting in a reduction in absorption of iron and subsequent iron deficiency anemia (IDA). In fact, the most frequent extra-intestinal manifestation (EIM) of CD is IDA, with a prevalence between 12 and 82% (in relation with the various reports) in patients with new CD diagnosis. The primary treatment of CD is the gluten-free diet (GFD), which is associated with adequate management of IDA, if present. Iron replacement treatment historically has been based on oral products containing ferrous sulphate (FS). However, the absorption of FS is limited in patients with active CD and unpredictable in patients on a GFD. Furthermore, a poor tolerability of this kind of ferrous is particularly frequent in patients with CD or with other inflammatory bowel diseases. Normalization from anemic state typically occurs after at least 6 months of GFD, but the process can take up to 2 years for iron stores to replenish.

Evaluation of Iron Status, Haemoglobin and Protein Levels of Pregnant Women in Owerri Metropolis

The study was done to determine iron status, haemoglobin and protein levels of pregnant women in owerri metropolis. A total of 100 pregnant women were recruited for this study. The mean Hb levels in group 1, group 2, and group 3· were 12.00±1.68g/dl, 10.06±1.J4g/dl and 10.96±1.19g/dl respectively. The mean Serum ferritin level of group 1 was 67.00±88.38ng/ml, group 2, 52.48±52.47ng/ml and group 3, 51.26±48.70ng/ml. The mean Serum iron in group 1, 2 and 3 were 46.72±16.41 g/dl, 79.59±63.24 g/dl and 83.35±53.04 g/dl respectively. In group 1, 2 and 3 the mean results. ( g/dl) of TIBC were 295.58 ± 109.53, 324.06 ± 178.00 and 319.88 ± 92.95 and % T.S (%) were 18.78 ± 11.77,26.59 ± 19.40 and 17.97 ± 10.87 percent respectively. The mean total protein was group 1,6.83±l1.77g/dl, group 2,6.39±0.70g/dl and group 3, 6.39 ±0.98 g/dl while the mean albumin (g/dl) in group 1, 2 and 3 were 4.84±0.47, 4.13±0.28 and 4.14±0.29 respectively. The mean values of globulin (g/dl) were 1.98 ± 0.91, 2.29 ± 0.87 and 1.89 ± 0.90 in groups 1, 2 and 3 respectively. As gestational age increased; serum ferritin, total protein, and albumin levels decreased while serum" iron and TIBC increased. The differences in the mean results between the groups were statistically significant (p<0.05) while % T.S and globulin levels when compared showed no significant difference (p>0.05). Iron status showed no statistical difference with increasing parity (p>0.05). However, from this study iron deficiency anaemia was most prevalent in second trimester; hence iron status estimation should be an integral part of routine antenatal care test during second trimester of each pregnancy for proper assessment and management of iron deficiency anaemia in pregnancy.

Gastrointestinal Endoscopic Outcome in Late Adolescent Women With Iron-Deficiency Anemia in Basrah-Iraq: A Multicenter Study.

BackgroundIron deficiency anemia (IDA) in late adolescent women has multiple pathophysiologies. Silent blood loss, celiac disease (CD), malignancies, and other gastrointestinal (GI) lesions receive much attention during IDA management. There is no consensus about endoscopic screening. Our study evaluates factors affecting GI endoscopic diagnosis for the etiology of IDA in late adolescent women.Materials and MethodsWe conducted an observational, multicenter retrospective analysis of 192 adolescent women with IDA admitted for GI endoscopic diagnosis from 2006 to 2016. Baseline measurements included hemoglobin, serum ferritin, mean corpuscular volume, serum iron, total iron-binding capacity, and transferrin saturation. We collected demographic characteristics, duration of hospital stay, the degree of severity of anemia, and endoscopic findings.ResultsThe mean age was 19±1 years (range 17 to 21 years), with mildly to moderately severe IDA. Patients received esophagogastroduodenoscopy (EGD, n=178) or colonoscopy (n=14). The mean hospital stay was 2.0±1.0 days. We found negative endoscopies (n=74), CD (n=85), gastric ulcer (n=19), malignancy (n=2), inflammatory bowel disease (n=1), and other nonsignificant endoscopic findings (n=11). We found no correlation between the duration of the hospital stay with the severity of IDA, no significant association between GI symptoms of the patients with endoscopic findings, and a significant but weak association between GI symptoms and serum ferritin.ConclusionsIn late adolescent women with IDA who have significant GI endoscopic lesions, the GI symptoms are of limited value in guiding the endoscopic diagnostic approach for evaluation of IDA.

Ferric carboxymaltose treatment for iron deficiency anemia in children with inflammatory bowel disease: Efficacy and risk of hypophosphatemia

BackgroundAlthough intravenous ferric carboxymaltose (FCM) is effective in treating iron deficiency anemia (IDA) in paediatric inflammatory bowel disease (pIBD), no data are available on its post-infusion related risks. AimsWe assessed the efficacy of FCM and the rate of post-infusion hypophosphatemia in a large cohort of children with IBD and IDA. MethodsAll children with IBD with IDA treated with FCM over 5-year period were reviewed. Disease activity, biohumoral assessment and treatments were evaluated at baseline, 4–6 and 12 weeks after each infusion. Results128 patients [median age at first infusion: 13 years] were identified, 81 (63.3%) were <14 years, 10 (7.8%) <6 years. Eighty-three children (64.8%) received one infusion, whilst 45 (35.2%) repeated infusions. A significant increase in Hb (p<0.001), iron (p<0.001) and ferritin (p<0.001) was observed 4–6 and 12 weeks post-infusion. Hb gain was unrelated to disease severity. Low baseline iron was the main predicting factor for repeated infusions (p<0.05). Three patients reported infusion reactions, none <6 years. Twenty-five children had low post-infusion serum phosphate (11 were <14 years, 3 <6 years). Two children developed severe hypophosphatemia. ConclusionsFCM administration is effective for IDA management in pIBD, including children <6 years. Due to the high prevalence of post-infusion hypophosphatemia, serum phosphate monitoring should be mandatory.

Investigation and management of iron deficiency anaemia in a specialist palliative care setting and the role of intravenous iron: a descriptive analysis of hospice data.

Anaemia is common in hospice populations and associated with significant symptom burden. Guidelines recommend investigating for and treating iron deficiency (ID), but there is little evidence of this practice in palliative care populations. This report describes the results of investigations for and subsequent management of ID in a UK hospice. This is a descriptive study of routine clinical data. Laboratory and clinical records were reviewed retrospectively for 12 months following the implementation, in August 2018, of routine investigation for ID amongst patients with clinically relevant anaemia in whom treatment would be considered. Absolute (AID) and functional iron deficiency (FID) were diagnosed using established definitions and treatments recorded. Iron status was evaluated in 112 cases, representing 25/110 (22.7%) of those with mild, 46/76 (60.5%) moderate and 41/54 (75.9%) severe anaemia. Twenty-eight (25%) were defined as having AID, 48 (42.8%) FID and 36 (32%) no ID. There was a significant difference between groups in symptoms triggering haemoglobin check and diagnosis, with a higher proportion of patients with classic symptoms of anaemia and gastrointestinal malignancy in those with AID. Intravenous iron was given on 12 occasions in the hospice with no major adverse events. Subjective symptom benefit in 7 cases and a statistically significant increase in overall mean haemoglobin were observed. This report describes the outcome of investigations for iron deficiency in patients with clinically significant anaemia in a UK hospice. Results indicate iron deficiency is common and can be safely treated with intravenous iron replacement, within current guidelines, in a hospice setting. Further research should define the optimum use of this approach in palliative care patients.

Iron Protein Succinylate in the Management of Iron Deficiency Anemia: A Comparative Study with Ferrous Sulphate at Low and High Therapeutic Doses.

Oral iron supplementation constitutes the first line treatment for iron deficiency anemia (IDA), with daily doses between 80 mg and 200 mg of elemental iron. Ferrous salts, such as ferrous sulphate (FeSO4), while efficacious, frequently give rise to gastrointestinal side effects. In the present paper we attempted to directly compare the efficacy of an alternative to the FeSO4 formulation, which presents a better tolerability profile, iron protein succinylate (Ferplex®). In a diet-induced anemia model, rats were treated by oral gavage with vehicle, FeSO4, or Ferplex® at a human-dose equivalent of 80 mg and 200 mg of elemental iron. We evaluated the change in anemia-related hematological and biochemical parameters, conducting a histological examination of the intestine at sacrifice. Results indicate that both types of iron supplementation are equally effective in the treatment of IDA, restoring hemoglobin, hematocrit, erythrocytes, free iron and transferrin levels in 15 days, with no statistical differences between treated groups and control. The impact of anemia on body weight was also attenuated following treatment with both iron supplements. Thrombocyte and reticulocyte levels, altered by the anemic condition, returned to homeostasis after 15 days of either FeSO4 or Ferplex® treatment. Importantly, the lower and higher doses of iron were equally effective, thus supporting the current school of thought which states that lower therapeutic doses are sufficient for management of IDA. In addition, the study shows for the first time that oral treatment with Ferplex® does not increase serum hepcidin. Finally, Ferplex® induced minimal iron depositions in the intestinal tissue compared to FeSO4.

The prevalence and clinical characteristics of restless legs syndrome in patients with iron deficiency anemia in Korea.

While the prevalence and clinical characteristics of restless legs syndrome (RLS) are known to vary according to ethnicity, a detailed evaluation of this condition among patients with iron deficiency anemia (IDA) has not yet been reported in an Asian population. We investigated the prevalence and clinical characteristics of RLS in patients with IDA in Korea compared with age- and sex-matched patients diagnosed with idiopathic RLS. This prospective single-center study was performed at a regional university hospital. Consecutive patients with IDA were enrolled over a 4-year period. Clinical interviews and laboratory tests were conducted at the first visit. RLS diagnosis was confirmed through face-to-face interviews. We randomly selected patients with idiopathic RLS without comorbid medical disorders from our sleep center dataset as control patients. The clinical characteristics of both groups were compared. We enrolled 124 patients with IDA. Fifty (40.3%) patients were diagnosed with RLS, with 82% exhibiting severe to very severe symptoms. Patients with IDA and RLS were older and reported more sleep deterioration than patients with IDA without RLS. Patients with IDA and RLS also had a more depressed mood and higher periodic limb movement index scores than patients with idiopathic RLS. The prevalence of RLS among patients with IDA in Korea was high, with the majority having severe to very severe symptoms. Patients with IDA and RLS had poorer sleep quality and more emotional problems than patients with IDA without RLS. Therefore, patients with IDA should be screened for RLS to prevent adverse effects on the quality of sleep and life.

Management of iron deficiency anemia in hemodialysis patients based on mean corpuscular volume

BackgroundTo manage the anemic status in hemodialysis (HD) patients, a well-balanced combination therapy based on the use of erythropoiesis-stimulating agents (ESAs) and iron supplementation is essential. Serum ferritin level and transferrin saturation rate (TSAT) are the current standard tests for screening iron deficiency status. However, these are not included in frequently checked regular blood measurements in many HD centers. Other parameters that could predict a hemoglobin (Hb) increase response from iron supplementation have yet to be established. To determine a frequently checked and regularly measured biomarker for predicting iron deficiency status, this study investigated the value of mean corpuscular volume (MCV) as a clinical parameter for HD patients receiving intravenous iron supplementation (Fe-IV) therapy.Methods and resultsOne hundred thirty four HD patients, 88 non-HD patients with anemia, and 50 HD patients on Fe-IV therapy from the Nozatomon clinic were assessed. Comparison of MCV values of anemic HD patients and anemic non-chronic kidney disease (CKD) patients showed that anemic HD patients had significantly higher MCV values (93.9 ± 7.3 fL) compared with anemic non-CKD patients (82.8 ± 8.8fL). Fifty HD patients, who received Fe-IV therapy at ten consecutive HD sessions (inclusion criteria: Hb ≤ 12.0 g/dL, TSAT < 20%, and serum ferritin < 100 ng/mL) showed a rapid increase during the Fe-IV period in MCV, Hb, and TSAT levels. After the completion of the Fe-IV therapy, MCV persisted at the increased levels, whereas Hb levels further increased and peaked at 1 month with a gradual decline after, largely influenced by ESA dosage reductions. The 50 patients were divided into three groups according to the MCV levels obtained immediately prior to the Fe-IV therapy (MCV ≤ 85 fL, 85 fL < MCV ≤ 90 fL, MCV > 90 fL), and Hb changes at 50 days after the initiation of the Fe-IV therapy were compared. All the patients in the MCV ≤ 85 fL group and most of the patients in the 85 fL < MCV ≤ 90 fL group showed linear and consistent Hb increase during the 50-day period. In marked contrast, patients in the MCV > 90 fL group showed dispersed trends in their Hb increase. The present study also revealed that successful ESA dosage reduction could be achieved after the Fe-IV therapy in both the MCV ≤ 85 fL and 85 fL < MCV ≤ 90 fL groups.ConclusionsThe present study underscored the value of MCV in perceiving iron deficiency status as well as predicting iron-based therapeutic response in HD patients.

Investigation and management of iron deficiency anaemia in a specialist palliative care setting and the role of intravenous iron: a descriptive analysis of hospice data

Background: Anaemia is common in hospice populations and associated with significant symptom burden. Guidelines recommend investigating for and treating iron deficiency (ID), but there is little evidence of this practice in palliative care populations. This report describes the results of investigations for and subsequent management of ID in a UK hospice. Methods: This is a descriptive study of routine clinical data. Laboratory and clinical records were reviewed retrospectively for 12 months following the implementation, in August 2018, of routine investigation for ID amongst patients with clinically relevant anaemia in whom treatment would be considered. Absolute (AID) and functional iron deficiency (FID) were diagnosed using established definitions and treatments recorded. Results: Iron status was evaluated in 112 cases, representing 25/110 (22.7%) of those with mild, 26/76 (60.5%) moderate and 41/54 (75.9%) severe anaemia. Twenty-eight (25%) were defined as having AID, 48 (42.8%) FID and 36 (32%) no ID. There was a significant difference between groups in symptoms triggering haemoglobin check and diagnosis, with a higher proportion of patients with classic symptoms of anaemia and gastrointestinal malignancy in those with AID. Intravenous iron was given on 12 occasions in the hospice with no major adverse events. Subjective symptom benefit in 7 cases and a significant increase in overall mean haemoglobin were observed. Conclusions: This report describes the outcome of investigations for iron deficiency in patients with clinically significant anaemia in a UK hospice. Results indicate iron deficiency is common and can be safely treated with intravenous iron replacement, within current guidelines, in a hospice setting. Further research should define the optimum use of this approach in palliative care patients.

Traitement par fer oral de l’anémie ferriprive lors de la grossesse : état des pratiques chez les sages-femmes

Iron deficiency anemia represents a public health issue which is usually managed by midwives. Because it is associated with maternal and fetal risks, a treatment is warranted. Oral iron represents the main option for treating this condition. Despite the existence of national and international guidelines no consensus about its modality of use has emerged so far. The primary objective of this study was to analyze midwives'practice with regards to iron deficiency anemia treatment using oral iron formulations. We conducted an observational and descriptive cross-sectional in a sample of midwives from the Gironde administrative region using a questionnaire. We obtained 85questionnaires from midwives working in private or public health facilities. Doses of iron and duration of treatment seem insufficient for a majority of responders. Folic acid and vitamin C are often associated with oral iron. Most midwives assess the efficacy of oral iron at one month with hemoglobin and ferritin levels. A significant fraction of these midwives shares similar practices which are in good accordance with the literature such as patient counselling with regards to drug intake, management of gastrointestinal side effects and inefficacity of oral iron. Noticeably, some of these midwives don't follow any guidelines. The majority of participants demonstrated practices in accordance with various national guidelines although no precise therapeutic algorithm is available as reference. Larger studies on the management of iron deficiency anemia in pregnancy by health professionals and harmonization of practices are necessary.

Dhatri Lauha in the management of iron deficiency anemia: A prospective open-label single-arm multi-center trial.

The burden of iron-deficiency anemia (IDA) remains persistently high in India due to the poor tolerability of oral iron supplementation. Therefore, more focus is required to explore traditional medicine for safe and effective options for managing IDA. To assess the clinical safety and efficacy of Dhatri Lauha in patients with IDA. An open-label, prospective, single-arm, multi-center trial was conducted at 12 centers with a sample size of 40 participants per study site. Patients with IDA aged 18-60 years with hemoglobin levels in the range of 6-10gm/dl, mean corpuscular volume (MCV) <80 fl, mean corpuscular hemoglobin concentration (MCHC) <34 μg/dl, serum ferritin <30 μg/dl and serum iron <50 μg/dl were included in the study. Dhatri Lauha 500 mg capsule was administered twice daily with lukewarm water after meals for 45 days. The primary outcome measure was the change in hemoglobin (Hb%) level from baseline to day 45. Secondary outcome measures included the change in MCV, MCHC, serum iron and ferritin levels, incidence of adverse events, and change in safety parameters (liver and kidney function tests). The mean (statistical) change in outcome measures from baseline to day 45 was compared using a paired sample t-test. Out of 458 participants enrolled in the study, 400 contributed to the final analysis. A significant difference was observed in the outcome parameters such as Hb%, MCV, MCHC, serum ferritin, and serum iron levels (P < 0.001) after 45 days of treatment. Mean Hb% changed from 8.46 ± 1.14 g/dl at baseline to 9.18 ± 1.61 g/dl on day 45 (P < 0.001). LFT and KFT were within the normal limits after the study period. No participant withdrew from the study due to adverse events. Dhatri Lauha is a safe intervention and can be expected to improve hemoglobin levels, red blood cell parameters, and iron stores in patients with IDA. Future RCTs with a larger sample size, standard care as control and a longer follow-up may produce more accurate and reliable results.

Review on Management of iron deficiency Anaemia with Ayurveda

Review on Management of iron deficiency Anaemia with Ayurveda

Revisiting Iron Metabolism, Iron Homeostasis and Iron Deficiency Anemia.

Iron deficiency anemia (IDA) is one of the commonest clinical scenarios especially in children, women of childbearing age, and elders. The crux of this review was revisiting iron homeostasis, mechanism of iron absorption, causes, laboratory diagnosis, and management of IDA. This narrative review is compiled after a relevant literature search from electronic databases including, but not limited to, Google, Google Scholar, PMC, PubMed, Science Direct, and Scopus. The key words used for searching relevant literature include iron, iron deficiency, iron deficiency anemia, iron metabolism, hepcidin, transferrin, causes of iron deficiency anemia, and laboratory diagnosis of iron deficiency anemia. Reference hema-tology books were also consulted. According to the published literature, about one mg of iron is required daily which equals its loss, although the iron requirement increases in pregnancy and lactating mothers. Dietary non heme iron (oxidized Fe3+) is reduced to the ferrous (Fe2+) form by ferrireductase present in the brush border of duodenal enterocytes. Ferrous iron is absorbed in the brush border of duodenal enterocytes through a carrier protein, divalent metal transporter 1 (DMT1). Heme iron is absorbed by the duodenal enterocytes through a mechanism that is not well understood or a receptor yet to be discovered. Transferrin receptor helps in the internalization of iron in the cells. Hepcidin acts as a gatekeeper and controls iron absorption by enterocytes and macrophages. IDA may be caused by decreased intake of iron, increased iron requirements or loss of iron from the body. Iron deficiency anemia is the most common nutritional anemia that affects large numbers of people in developed as well as in developing countries. It is estimated that approximately 2 billion people around the world have IDA. Microcytosis with marked reduction in serum iron, decreased % saturation of transferrin, low ferritin, and reduced or even undetectable hepcidin are the laboratory features of IDA. In addition, total iron binding capacity and soluble transferrin receptors increase significantly in IDA. Management of IDA is incomplete if the underlying cause is not ruled out and left untreated.

Effectiveness of a Planned Teaching Programme to Educate Adolescent Girls in the Avoidance and Dealing with Iron Deficiency Anaemia in a Selected School of Bilaspur District

Background: Nowadays young adolescents face many problems because of their lifestyle modifications such as eating junk foods, fast foods, snacking, and skipping meals. Some adolescents are undernourished due to a lack of awareness regarding dietary iron and poor socioeconomic status. These are quite common among urban adolescent girls. Iron deficiency anaemia is the most prevalent nutritional disorder in the world today. Iron is a necessary mineral for body function and good health. A lack of iron in the blood can lead to iron deficiency anaemia, which is a very common nutritional deficiency among children and adolescents. Objective: This study is aimed to analyse the effectiveness of a planned teaching programme to educate adolescent girls in the prevention and management of iron deficiency anaemia in a selected school of Bilaspur district. Method: Convenient sampling technique and structured questionnaire were used in the study. Result and Conclusion: The findings revealed that about 38% of the adolescent girls belonged to the age group of 14.1-15 years, 85% belonged to the Hindu religion, 48% had family income &gt; 30,000 INR, 63% belonged to nuclear families, fathers of 60% of the adolescent girls were government employees, mothers of 48% of the adolescent girls were housewives, 78% of the adolescent girls belonged to urban areas, and 48% of the adolescent girls had got the information through mass media. The distribution of the adolescent girls among the 9th, 10th, 11th, and 12th standards was found to be equal (25% each). The assessment of the overall pre-test knowledge level of adolescent girls shows that 3% had good knowledge, 86% had average knowledge, and 11% had below-average knowledge.

A COMPARATIVE RANDOMIZED CLINICAL TRIAL OF NAVAYAS LOUHA SYRUP AND NISHA LOUHA SYRUP IN THE MANAGEMENT OF IRON DEFICIENCY ANEMIA IN INDIAN CHILDREN WITH SPECIAL REFERENCE TO PANDU ROGA

Iron deficiency is the most usual dietary deficiency worldwide, approximately 25% of the world’s population suffering from iron deficiency anemia according to the World Health Organization. A Neonate has total body iron of 250 mg (80 mg/kg), obtained from maternal sources. In the first 6 months of life, during the period when the infant gets an iron-deficient milk diet, this amount decreases to 60 mg/kg. Infants fed with cow’s milk are at greater risk to develop iron deficiency anemia because calcium from cow’s milk is competing with iron for absorption. There are a large number of formulations (like Navayas Louha Syrup, Nisha Louha Syrup etc.) that are mentioned to prevent iron deficiency anemia in Indian children. Despite lack of scientific data regarding the clinical efficacy of Navayas Louha Syrup and Nisha Louha Syrup, an effort has been done to present the current scenario. 60 anemic patients of either sex age between 1-15 years were randomly selected from Kaumarabhritya O.P.D. and I.P.D. of Rani Dullaiya Post Graduate Ayurvedic College and Hospital, Bhopal (M.P), India. Overall, in the study Navayas Louha is 74.53% and Nisha Louha is 69.34% having clinical efficacy. The study was showed in clinical trial efficacy of Navayas Louha syrup is better than Nisha Louha syrup in the management of iron deficiency anemia in Indian children.

An assessment of the adequacy of iron deficiency anaemia management in the Namibian private healthcare system.

Anaemia, a condition characterized by reduced oxygen-carrying capacity, is a widespread public health problem with major consequences for human health as well as social and economic development. Prompt and accurate diagnosis as well as effective management of iron deficiency anaemia (IDA) is important to prevent the undesired adverse clinical outcomes. The purpose of the study was to assess the adequacy of IDA diagnosis and management within the Namibian private healthcare system. In this study, we used a quantitative, descriptive research design and data collection methods. The design was also nonexperimental in nature, employing a survey instrument to collect data. In total, 51 questionnaires were administered to private medical practitioners. The surveyed medical practitioners used different Standard Treatment Guidelines (STGs) in managing IDA cases, with the majority (76.5%) using the Namibia STGs. The other guidelines and their usage rates were as follows: World Health Organization guidelines (39.2%), Standard Treatment Guidelines and Essential Medicine List for South Africa (19.6%) and Essential Medicine List and Standard Treatment Guidelines for Zimbabwe (19.6%). Most of the medical practitioners used Namibian STGs although others used other treatment guidelines at their discretion. The study concluded that medical practitioners follow different guidelines and reference documents when dealing with patients with suspected IDA. Adherence to a single reference document would enable standardization of clinical practice. Management of IDA in the Namibian private healthcare system could be improved. To ensure adequate IDA management and prompt resolution of iron deficiency anaemia, we recommended the need to review the Namibia Standard Treatment guidelines and to ensure that training on the guidelines is offered.

Effect of oral iron and intravenous iron sucrose on pregnancy related outcome among pregnant females with iron deficiency anemia

Introduction: Intravenous iron sucrose and oral iron therapy are the primary therapeutic modalities for management of iron deficiency anaemia during pregnancy, but its efficacy during pregnancy is still a matter of argument among healthcare personnel. Therefore the objective of this study is to compare the effect of oral iron and intravenous iron sucrose on pregnancy related outcome among pregnant females with iron deficiency anemia. Materials and Methods: Randomized clinical trial was conducted among females between 14 to 36 weeks gestation with iron deficiency anemia who were managed either with oral ferrous sulphate or intravenous iron sucrose therapy. Chi-square test was used for statistical analysis with p Results: About 11.25% of the study subjects had the complication of abruption/ Post-Partum hemorrhage or had the need of blood transfusion in oral group. No significant difference in respect to maternal complications as well as mode of delivery was observed in between the two groups. In intravenous group proportion of appropriate for gestational age newborns (AGA) were significantly higher than the oral group (p Conclusions: Intravenous iron sucrose use for treatment of iron deficiency anaemia could reduce morbidities from iron deficiency and have better foetal outcome in terms of appropriate for gestational age in newborns. Keywords: Anaemia, Haemoglobin, Iron sucrose.